Modifiedmedical mutual - ohioPolicy AHS - G2121

Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease

Defines coverage for fecal and serologic laboratory tests used to diagnose or monitor inflammatory bowel disease (IBD) including ulcerative colitis and Crohn's disease for Medical Mutual - Ohio members.

Policy Summary

Payermedical mutual - ohio

PolicyLaboratory Testing for the Diagnosis of Inflammatory Bowel Disease

Policy CodePolicy AHS - G2121

Change TypeMaterial updates: coverage clarifications, code additions, renumbering

Effective DateFeb 1, 2026

Next Review DateSep 4, 2025

Key ActionOrder fecal calprotectin (preferred) only when indicated for differential diagnosis of IBS vs IBD or for monitoring IBD; if both calprotectin and lactoferrin are ordered concurrently, only calprotectin will be approved.

SourceLink

POLICY UPDATE CHANGES

Fecal calprotectin or fecal lactoferrin testing MEETS COVERAGE CRITERIA for: a) differentiating non-inflammatory GI disease from inflammatory GI disease; b) monitoring individuals with IBD (assess response to therapy or relapse).

For all other situations not described above, fecal calprotectin and fecal lactoferrin testing DOES NOT MEET COVERAGE CRITERIA.

Former CC2 was renumbered to CC4 and edited: multianalyte serum biomarker panels (with or without algorithmic analysis) designed to distinguish IBD from non-IBD or to diagnose/monitor IBD DO NOT MEET COVERAGE CRITERIA (examples: ibs-smart™, IBSchek®, PredictSURE IBD™, Prometheus®).

Added CPT codes 83630 and 83993 and CPT II code 0598U (effective 10/1/2025).

New Note 1: Fecal calprotectin is the preferred biomarker; if both fecal calprotectin and fecal lactoferrin are ordered together, only fecal calprotectin will be approved.

50common fecal calprotectin cutoff cited

150

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

young patient / post-op cutoff

93% / 94%pooled sens / spec (IBD vs IBS)

3multianalyte tests listed as not meeting criteria

3new/added CPT/HCPCS codes

Coverage Criteria for Fecal and Serologic Tests

Covered indications consistent with medical society guidance

Covered when consistent with medical society guidance:

ANY of the following

Fecal calprotectin testing (preferred fecal biomarker) for the differential diagnosis between non-inflammatory gastrointestinal disease (e.g., irritable bowel syndrome) and inflammatory gastrointestinal disease (e.g., inflammatory bowel disease).
If fecal calprotectin and fecal lactoferrin are ordered at the same time, only fecal calprotectin will be approved. (Note 1)
Fecal lactoferrin testing when used as an alternative to fecal calprotectin for distinguishing IBD from non-inflammatory disorders, when testing aligns with guideline-recommended use and local care pathways.
Use of fecal calprotectin or fecal lactoferrin to monitor individuals with known IBD (e.g., assess response to therapy or detect relapse), when results will inform clinical management (for example, to guide need for endoscopic assessment or treatment adjustment) and are applied consistent with guideline thresholds (such as AGA/ACG/ECCO recommendations).
AGA and ACG guidance support using fecal calprotectin thresholds (e.g., ~50–150 µg/g depending on context) to triage need for endoscopy or treatment changes.

Infection/immunization screening

Infection and immunization screening (as part of IBD workup):

ALL of the following

Assess and document immunization status when evaluating or preparing patients with suspected or confirmed IBD.
Consider screening for latent tuberculosis prior to initiation of immunosuppressive therapy or biologic agents, per guideline recommendations.
Stool testing to rule out enteric pathogens including Clostridioides difficile when clinically indicated (e.g., suspected infectious diarrhea or possible infectious trigger of flare).
NICE, ACG, and ECCO guidance recommend targeted pathogen testing rather than routine broad stool pathogen panels for all patients.

Not covered: Stool biomarkers for other indications

Not covered — stool biomarkers for other indications:

ANY of the following

Fecal calprotectin or fecal lactoferrin testing for indications other than: (1) differentiating inflammatory from non-inflammatory bowel disease, or (2) monitoring known IBD to guide management. These other uses DO NOT MEET COVERAGE CRITERIA.
Routine use of fecal biomarkers for population screening, asymptomatic surveillance without clinical indication, or for non-IBD gastrointestinal conditions where evidence of clinical benefit is lacking.

Not covered: Multianalyte serum biomarker panels

Not covered — multianalyte serum biomarker panels and combinatorial serologic/genetic tests:

ANY of the following

Multianalyte serum biomarker panels (with or without algorithmic analysis) designed to distinguish between IBD and non-IBD, or intended to diagnose or monitor IBD (examples include, but are not limited to, ibs-smart™, IBSchek®, PredictSURE IBD™, Prometheus® testing) DO NOT MEET COVERAGE CRITERIA.
Serologic antibody panels and combinatorial serologic-genetic testing approaches are not covered for routine diagnosis, prognosis, or monitoring of IBD given limited sensitivity, specificity, and lack of evidence that routine use improves clinically meaningful outcomes.
Individual serologic markers (e.g., pANCA, ASCA) and multi-antibody panels are discouraged for routine diagnostic or prognostic use; these tests may be considered only in exceptional clinical scenarios where they would change management and documented rationale is provided, but generally DO NOT MEET COVERAGE CRITERIA.

Applicable Procedure and Proprietary Codes

Applicable CPT/HCPCS Procedure Codes (group 1)CPT

81401	Molecular pathology procedure, Level 2
81479	Unlisted molecular pathology procedure
82397	Chemiluminescent assay
83516	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
83630	Lactoferrin, fecal; qualitative
83993	Calprotectin, fecal
86021	Antibody identification; leukocyte antibodies
86036	Antineutrophil cytoplasmic antibody (ANCA); screen, each antibody
86037	Antineutrophil cytoplasmic antibody (ANCA); titer, each antibody

1–10 of 14

1/2

Applicable Proprietary/Temporary Codes (group 2)HCPCS

0164U	Immunoassay for anti-CdtB and anti-vinculin antibodies (ib s-smart™)
0176U	Cytolethal distending toxin B (CdtB) and vinculin IgG antibodies by immunoassay (IBSchek®)
0203U	Autoimmune (IBD), mRNA gene expression profiling, 17 genes (PredictSURE IBD™)
0598U	IgG antibodies to 18 food items by microarray-based immunoassay (inFoods® IBS Test)

Added/Relevant Test Codesmixed

83630	Calprotectin; fecal
83993	Lactoferrin; fecal
0598U	Multianalyte assay with algorithmic analysis (example proprietary/temporary code listed in policy)

Applicable CPT/HCPCS procedure codesmixed

No codes listed

No explicit CPT/HCPCS/ICD codes in this sectionmixed

No codes listed

No CPT/HCPCS/ICD codes listed in these chunksmixed

No codes listed

Fecal calprotectin cutoffs — common thresholds

Common cutoff50 µg/g (commonly quoted by manufacturers)

Young patients / postoperative threshold150 µg/g (recommended cutoff in young patients and reported optimal threshold for postoperative Crohn's recurrence)

Study/normalization value100 µg/g (used in some studies for normalization)

Fecal calprotectin thresholds used in studies and guidelines

Range reported in studies50, 100, 150, 200 µg/g (thresholds evaluated across meta-analyses and studies)

Provider Actions, Billing, and Authorization

Prior Authorization

Prior authorization and benefit verification

Verify member benefits and prior authorization requirements at the time of service. Coverage decisions depend on the individual’s benefit plan; applicable government (Medicare/Medicaid) policies supersede this policy.

No prior authorization requirements are specified in this excerpt — providers should still verify benefits and any payer-specific authorization processes.
If there is a conflict with applicable government policy (e.g., LCD/NCD), the government policy supersedes.

Billing Rule

Billing codes listed — confirm before billing

Use the listed CPT/HCPCS and miscellaneous codes for billing and confirm coding and prior authorization with the payer before claim submission.

Background and Context

Inflammatory bowel disease (IBD) principally includes two major disorders: ulcerative colitis (UC) and Crohn's disease (CD), which differ in anatomic involvement and pathology. Differentiation between IBD and non-inflammatory disorders such as irritable bowel syndrome (IBS) relies on clinical assessment plus endoscopic, imaging, histologic and laboratory data. Fecal biomarkers—particularly fecal calprotectin—are noninvasive tests that correlate with intestinal inflammation and are useful to help distinguish IBD from IBS and to monitor disease activity. The policy supports fecal calprotectin or fecal lactoferrin when used for these purposes and clarifies that fecal calprotectin is the preferred stool biomarker.

Definitions and Key Terms

Ulcerative colitis (UC) definition

DefinitionChronic inflammatory condition limited to the mucosal layer of the colon beginning at the rectum and extending proximally in a continuous fashion.

PathologyRelapsing and remitting mucosal inflammation confined to the colon

Clinical relevanceDistinguished from Crohn's disease by continuous colonic involvement and mucosal-limited inflammation

Crohn's disease (CD) definition

DefinitionPatchy transmural inflammation of the gastrointestinal tract (skip lesions) that can lead to sinus tracts, fistulae, strictures, and obstruction.

PathologyTransmural inflammation that can affect any part of the GI tract

Policy Revision History

2026-02-01policy_effective_dateLatest

Policy effective date (AHS - G2121) as updated to incorporate fecal calprotectin/lactoferrin coverage criteria and related changes.

2025-10-01coding_addition

Added CPT codes 83630 and 83993 and HCPCS/proprietary code 0598U to align coding with coverage decisions (effective 10/1/2025).

2025-09-04revision

Policy Summary

Payermedical mutual - ohio

PolicyLaboratory Testing for the Diagnosis of Inflammatory Bowel Disease

Policy CodePolicy AHS - G2121

Change TypeMaterial updates: coverage clarifications, code additions, renumbering

Effective DateFeb 1, 2026

Next Review DateSep 4, 2025

SourceLink

On This Page

Guideline differentiation threshold~50–100 µg/g or cutoff >50–100 µg/g (ACG recommendation to differentiate inflammatory vs noninflammatory colonic disease)

UC monitoring / rule‑in threshold150 µg/g (AGA uses >150 µg/g to identify active inflammation in UC; <150 µg/g to help rule out activity)

Postoperative recurrence example>150 µg/g associated with diagnostic accuracy for endoscopic postoperative recurrence (optimal at 150 µg/g in meta-analysis)

Timing for fecal calprotectin to assess mucosal healing

Timing to assess mucosal healingApproximately 3 to 6 months after treatment initiation (fecal calprotectin may be used as a surrogate for mucosal healing)

Use with other assessmentsFC should be combined with clinical parameters and endoscopy when determining response to therapy

Guideline sourceECCO-ESGAR guidance recommends FC ~3–6 months for mucosal healing assessment

Applicable procedure codes include: 81401, 81479, 82397, 83516, 83520, 83630, 83993, 86021, 86036, 86037, 86255, 86671, 88346, 88350, 0164U, 0176U, 0203U, 0598U.
Providers should confirm correct code selection and any prior authorization/billing rules with Medical Mutual - Ohio prior to testing or billing.

Denial Risk

Denial risk for serologic markers and unsupported panels

Tests and panels that do not meet coverage criteria risk claim denial. Specifically, serologic markers and multianalyte serologic/genetic panels are not covered for IBD diagnosis or monitoring per this policy.

Serologic markers (e.g., ANCA, ASCA, anti-CBir1, anti-I2, anti-chitobioside/antimannobioside, pyruvate kinase M2) DO NOT MEET COVERAGE CRITERIA for workup and monitoring of IBD — ordering these may result in denial.
Multianalyte serum biomarker panels and proprietary tests (e.g., ibs-smart™, IBSchek®, PredictSURE IBD™, Prometheus®) DO NOT MEET COVERAGE CRITERIA and may be denied.

Documentation Required

Documentation and test validation guidance

Documentation expectations for medically necessary testing: laboratory results are complementary to clinical, endoscopic, radiologic, and histologic findings. Providers should retain clinical documentation to support covered indications.

No additional specific provider documentation requirements are specified in this excerpt beyond usual medical record documentation that supports the covered indication.
Laboratory-developed tests (LDTs) must be validated by performing laboratories; FDA-cleared/approved assays exist for some calprotectin tests and may be referenced in interpretation.

Note

Operational notes — step therapy and concurrent biomarker ordering

Step therapy, quantity limits, and explicit denial triggers are not specified in this excerpt. When fecal calprotectin and fecal lactoferrin are ordered together, only fecal calprotectin will be approved.

No step therapy requirements are specified.
If both fecal calprotectin and fecal lactoferrin are ordered concurrently, only fecal calprotectin will be approved.
There are no explicit additional denial triggers listed in this excerpt beyond non-covered indications and unsupported tests/panels.

Clinical relevanceMay produce complications (fistulae, strictures) not typical of UC

Fecal calprotectin (FC) definition

DefinitionA neutrophil-derived protein measured in stool that correlates with intestinal inflammation and is stable in feces for up to seven days; used to distinguish IBD from IBS and to monitor disease activity.

BiologyReleased into the intestinal lumen from neutrophils during mucosal inflammation

Clinical usesDifferentiating IBD from noninflammatory disorders and monitoring response to therapy or relapse

Fecal calprotectin — alternate chunk references

Alternate referencesDescribed across ACG and AGA guidance as a stool biomarker to detect intestinal inflammation and aid differentiation of IBD vs IBS; stability and assay variability noted in reviews.

Assay variability noteDifferent manufacturers' assays show variability; standardization efforts have been recommended.

Reference sourcesACG, AGA, Nakov et al. reviews cited for clinical context and assay performance

Serologic antibody testing definition

DefinitionBlood antibody tests (e.g., ASCA, pANCA, anti-CBir1, anti-OmpC) evaluated to help differentiate CD vs UC or predict phenotype, but with limited sensitivity and not recommended for routine diagnosis or prognosis.

Guideline stanceACG and ECCO recommend against routine use of serologic antibody testing to establish diagnosis or prognosis for UC/CD.

Clinical roleMay have adjunctive or research roles but limited clinical utility for routine workup or monitoring.

Fecal calprotectin (fCal) — additional description

Additional descriptionFecal calprotectin (fCal) is a fecal neutrophil protein marker accurate for colonic inflammation and useful as a noninvasive marker for diagnosis and monitoring of IBD.

Practical notesfCal and fecal lactoferrin are safe, noninvasive, generally available, and can identify IBD with good accuracy compared with serologic tests.

StabilityHomogeneously distributed in feces and stable at room temperature for days, facilitating collection and testing.

Fecal lactoferrin (FL) definition

DefinitionA fecal-derived marker of intestinal inflammation similar to calprotectin and diagnostically useful to identify IBD.

Use caseCan be used alongside FC and CRP to help rule out inflammatory disease in patients with suspected IBS with diarrhea.

Practical noteBoth FL and FC are diagnostically useful and may be superior to CRP/ESR for discriminating IBD from IBS.

pANCA / ASCA definition and limits

DefinitionpANCA and ASCA are serologic antibodies historically used to aid differentiation between UC and CD but have limited sensitivity and specificity.

Guideline positionWGO, ECCO, and ACG note these tests have limited diagnostic value and are not recommended for routine classification of UC vs CD.

Clinical limitationMay be positive in atypical settings and have insufficient accuracy to replace endoscopic or imaging diagnostics.

Fecal calprotectin — further notes

Further notesFecal calprotectin is widely cited for differentiating IBD from functional disorders and for monitoring disease activity and postoperative recurrence.

Assay considerationsOptimal cutoffs vary by setting; positive results may be influenced by infectious gastroenteritis and should sometimes be repeated 2–3 weeks later if in the 50–150 µg/g range.

Evidence baseMultiple meta-analyses and guideline statements support its clinical use but emphasize variability and context-dependent thresholds.

Serologic markers — additional notes

Additional serologic notesMultiple serologic antibodies (e.g., anti-CBir1, antiglycan antibodies) have been studied and may associate with phenotype or complications but do not reliably predict outcomes for routine care.

Research vs clinical useThese markers are more often used in research or adjunctive contexts rather than routine diagnostic pathways.

Example referencesLiterature citations include Targan et al. and other studies exploring association with disease phenotype.

Preferred stool biomarker — calprotectin approval preference when both ordered

Preferred stool biomarkerFecal calprotectin is the preferred stool biomarker; if both fecal calprotectin and fecal lactoferrin are ordered concurrently, only fecal calprotectin will be approved.

Documentation expectationWhen both tests are ordered, documentation should justify the testing choice as only FC is approved in concurrent orders.

Policy changeThis preference was added in the 09/04/2025 revision history.

Commercial panels — multianalyte serum biomarker panels not meeting coverage

Definition / policy stanceCommercial multianalyte serum biomarker panels (with or without algorithmic analysis) intended to distinguish IBD from non-IBD or to diagnose/monitor IBD are considered not meeting coverage criteria.

Examples listedExamples listed in the policy include ibs-smart™, IBSchek®, PredictSURE IBD™, and Prometheus® testing.

Coverage implicationThese panels are excluded from coverage per the revised CC4 (formerly CC2).

Reviewed and updated background, guidelines, and evidence references; combined contents of prior G2061 fecal calprotectin policy into this policy and added new coverage criteria (CC1 and CC2) specifying covered uses and exclusions; renumbered and edited former CC2 (now CC4) clarifying multianalyte serum panels are not covered; added Note 1 preferring fecal calprotectin when both tests ordered.